Vertex Receives EU’s MAA for Symkevi (tezacaftor/ivacaftor) + Kalydeco (Ivacaftor) to Treat Patients with CF aged ≥12yrs. with Mutations in CFTR gene

 Vertex Receives EU’s MAA for Symkevi (tezacaftor/ivacaftor) + Kalydeco (Ivacaftor) to Treat Patients with CF aged ≥12yrs. with Mutations in CFTR gene

Vertex Receives EU’s MAA for Symkevi (tezacaftor/ivacaftor) + Kalydeco (Ivacaftor) to Treat Patients with CF aged ≥12yrs. with Mutations in CFTR gene

Shots:

  • The approval is based on the results of two P-III studies EVOLVE & EXPAND assessing Symkevi + Kalydeco vs PBO in 750 patients with CF having two copies of the F508del mutation or with one F508del mutation & a copy of either of 14mutations showing CFTR residual activity
  • P-III EVOLVE & EXPAND results: mean absolute change in ppFEV1 (4.0%, 6.8%); well tolerated. The combination is approved by the US FDA & Health Canada in Feb, 2018 & Mar, 2018 respectively and is marketed as Symdeko in the US and Canada
  • Symkevi is developed to detect mutations in CFTR gene. Additionally, EMA has recommended to maintain the Orphan Drug Designation for the combination

Click here to read full press release/ article | Ref: Vertex Pharmaceutical| Image: Boston Herald

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post